Biofidelity

Hear experts address the gaps and limitations of CGP by using innovative simplified genomic profiling solutions that work for challenging samples not analyzable by CGP. Aspyre is a breakthrough technology that allows detection of DNA- and RNA-based biomar

Biofidelity And Cellcarta Partner To Deploy Aspyre Lung In Global Clinical Trials. Aspyre Lung simplifies the detection of established non-small cell lung cancer (NSCLC) biomarkers by analyzing both DNA and RNA from tissue and blood using a streamlined fo

Context L.G. is a 71-year-old retired accountant who began experiencing symptoms associated with lung cancer, including shortness of breath and persistent cough. Concerned about his symptoms, he sought medical help from his primary care physician, who not

Context B.B., a 62-year-old piano teacher and avid hiker, began experiencing symptoms associated with lung cancer, including sudden shortness of breath and a persistent cough. Concerned, she sought medical help from a pulmonologist referred by her primary

With more than 25 FDA approved therapies that target genomic mutations, treatment options for patients with non-small cell lung cancer (NSCLC) have improved considerably in the last 20 years. These target therapies dramatically improve clinical outcomes a

See the workflow for Aspyre Lung in the video below.

Aspyre Lung identifies established NSCLC biomarkers in tissue or blood. View full product information Simple A straightforward, 4-step workflow on existing qPCR platforms. No need to invest in expensive hardware, data handling, or bioinformatics. Reliable